348 related articles for article (PubMed ID: 35123652)
1. A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection.
Beaudoin-Bussières G; Chen Y; Ullah I; Prévost J; Tolbert WD; Symmes K; Ding S; Benlarbi M; Gong SY; Tauzin A; Gasser R; Chatterjee D; Vézina D; Goyette G; Richard J; Zhou F; Stamatatos L; McGuire AT; Charest H; Roger M; Pozharski E; Kumar P; Mothes W; Uchil PD; Pazgier M; Finzi A
Cell Rep; 2022 Feb; 38(7):110368. PubMed ID: 35123652
[TBL] [Abstract][Full Text] [Related]
2. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
3. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
Liu L; Wang P; Nair MS; Yu J; Rapp M; Wang Q; Luo Y; Chan JF; Sahi V; Figueroa A; Guo XV; Cerutti G; Bimela J; Gorman J; Zhou T; Chen Z; Yuen KY; Kwong PD; Sodroski JG; Yin MT; Sheng Z; Huang Y; Shapiro L; Ho DD
Nature; 2020 Aug; 584(7821):450-456. PubMed ID: 32698192
[TBL] [Abstract][Full Text] [Related]
4. The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody.
Chan CEZ; Seah SGK; Chye H; Massey S; Torres M; Lim APC; Wong SKK; Neo JJY; Wong PS; Lim JH; Loh GSL; Wang D; Boyd-Kirkup JD; Guan S; Thakkar D; Teo GH; Purushotorman K; Hutchinson PE; Young BE; Low JG; MacAry PA; Hentze H; Prativadibhayankara VS; Ethirajulu K; Comer JE; Tseng CK; Barrett ADT; Ingram PJ; Brasel T; Hanson BJ
PLoS One; 2021; 16(6):e0253487. PubMed ID: 34161386
[TBL] [Abstract][Full Text] [Related]
5. Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2.
Lim SA; Gramespacher JA; Pance K; Rettko NJ; Solomon P; Jin J; Lui I; Elledge SK; Liu J; Bracken CJ; Simmons G; Zhou XX; Leung KK; Wells JA
MAbs; 2021; 13(1):1893426. PubMed ID: 33666135
[TBL] [Abstract][Full Text] [Related]
6. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects.
Jennewein MF; MacCamy AJ; Akins NR; Feng J; Homad LJ; Hurlburt NK; Seydoux E; Wan YH; Stuart AB; Edara VV; Floyd K; Vanderheiden A; Mascola JR; Doria-Rose N; Wang L; Yang ES; Chu HY; Torres JL; Ozorowski G; Ward AB; Whaley RE; Cohen KW; Pancera M; McElrath MJ; Englund JA; Finzi A; Suthar MS; McGuire AT; Stamatatos L
Cell Rep; 2021 Jul; 36(2):109353. PubMed ID: 34237283
[TBL] [Abstract][Full Text] [Related]
7. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies.
Barnes CO; West AP; Huey-Tubman KE; Hoffmann MAG; Sharaf NG; Hoffman PR; Koranda N; Gristick HB; Gaebler C; Muecksch F; Lorenzi JCC; Finkin S; Hägglöf T; Hurley A; Millard KG; Weisblum Y; Schmidt F; Hatziioannou T; Bieniasz PD; Caskey M; Robbiani DF; Nussenzweig MC; Bjorkman PJ
Cell; 2020 Aug; 182(4):828-842.e16. PubMed ID: 32645326
[TBL] [Abstract][Full Text] [Related]
8. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein.
Suryadevara N; Shrihari S; Gilchuk P; VanBlargan LA; Binshtein E; Zost SJ; Nargi RS; Sutton RE; Winkler ES; Chen EC; Fouch ME; Davidson E; Doranz BJ; Chen RE; Shi PY; Carnahan RH; Thackray LB; Diamond MS; Crowe JE
Cell; 2021 Apr; 184(9):2316-2331.e15. PubMed ID: 33773105
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.
Su W; Sia SF; Schmitz AJ; Bricker TL; Starr TN; Greaney AJ; Turner JS; Mohammed BM; Liu Z; Choy KT; Darling TL; Joshi A; Cheng KM; Wong AYL; Harastani HH; Nicholls JM; Whelan SPJ; Bloom JD; Yen HL; Ellebedy AH; Boon ACM
mBio; 2021 Oct; 12(5):e0239521. PubMed ID: 34517754
[TBL] [Abstract][Full Text] [Related]
11. Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease.
Golden JW; Zeng X; Cline CR; Garrison AR; White LE; Fitzpatrick CJ; Kwilas SA; Bowling PA; Fiallos JO; Moore JL; Sifford WB; Ricks KM; Mucker EM; Smith JM; Hooper JW
J Gen Virol; 2021 May; 102(5):. PubMed ID: 33961540
[TBL] [Abstract][Full Text] [Related]
12. Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations.
Dussupt V; Sankhala RS; Mendez-Rivera L; Townsley SM; Schmidt F; Wieczorek L; Lal KG; Donofrio GC; Tran U; Jackson ND; Zaky WI; Zemil M; Tritsch SR; Chen WH; Martinez EJ; Ahmed A; Choe M; Chang WC; Hajduczki A; Jian N; Peterson CE; Rees PA; Rutkowska M; Slike BM; Selverian CN; Swafford I; Teng IT; Thomas PV; Zhou T; Smith CJ; Currier JR; Kwong PD; Rolland M; Davidson E; Doranz BJ; Mores CN; Hatziioannou T; Reiley WW; Bieniasz PD; Paquin-Proulx D; Gromowski GD; Polonis VR; Michael NL; Modjarrad K; Joyce MG; Krebs SJ
Nat Immunol; 2021 Dec; 22(12):1503-1514. PubMed ID: 34716452
[TBL] [Abstract][Full Text] [Related]
13. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection.
Winkler ES; Gilchuk P; Yu J; Bailey AL; Chen RE; Chong Z; Zost SJ; Jang H; Huang Y; Allen JD; Case JB; Sutton RE; Carnahan RH; Darling TL; Boon ACM; Mack M; Head RD; Ross TM; Crowe JE; Diamond MS
Cell; 2021 Apr; 184(7):1804-1820.e16. PubMed ID: 33691139
[TBL] [Abstract][Full Text] [Related]
14. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite.
Cerutti G; Guo Y; Zhou T; Gorman J; Lee M; Rapp M; Reddem ER; Yu J; Bahna F; Bimela J; Huang Y; Katsamba PS; Liu L; Nair MS; Rawi R; Olia AS; Wang P; Zhang B; Chuang GY; Ho DD; Sheng Z; Kwong PD; Shapiro L
Cell Host Microbe; 2021 May; 29(5):819-833.e7. PubMed ID: 33789084
[TBL] [Abstract][Full Text] [Related]
15. MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants.
Lee S; Jang S; Kang J; Park SB; Han YW; Nam H; Kim M; Lee J; Cho KJ; Kim J; Oh M; Ryu J; Seok JH; Kim Y; Lee JB; Park MS; Kim YS; Park H; Kim DS
Front Immunol; 2021; 12():778829. PubMed ID: 34868052
[TBL] [Abstract][Full Text] [Related]
16. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies.
Finkelstein MT; Mermelstein AG; Parker Miller E; Seth PC; Stancofski ED; Fera D
Viruses; 2021 Jan; 13(1):. PubMed ID: 33477902
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies.
Li D; Edwards RJ; Manne K; Martinez DR; Schäfer A; Alam SM; Wiehe K; Lu X; Parks R; Sutherland LL; Oguin TH; McDanal C; Perez LG; Mansouri K; Gobeil SMC; Janowska K; Stalls V; Kopp M; Cai F; Lee E; Foulger A; Hernandez GE; Sanzone A; Tilahun K; Jiang C; Tse LV; Bock KW; Minai M; Nagata BM; Cronin K; Gee-Lai V; Deyton M; Barr M; Von Holle T; Macintyre AN; Stover E; Feldman J; Hauser BM; Caradonna TM; Scobey TD; Rountree W; Wang Y; Moody MA; Cain DW; DeMarco CT; Denny TN; Woods CW; Petzold EW; Schmidt AG; Teng IT; Zhou T; Kwong PD; Mascola JR; Graham BS; Moore IN; Seder R; Andersen H; Lewis MG; Montefiori DC; Sempowski GD; Baric RS; Acharya P; Haynes BF; Saunders KO
Cell; 2021 Aug; 184(16):4203-4219.e32. PubMed ID: 34242577
[TBL] [Abstract][Full Text] [Related]
18. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
Liu X; Drelich A; Li W; Chen C; Sun Z; Shi M; Adams C; Mellors JW; Tseng CT; Dimitrov DS
Vaccine; 2020 Oct; 38(46):7205-7212. PubMed ID: 33010978
[TBL] [Abstract][Full Text] [Related]
19. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody.
Rappazzo CG; Tse LV; Kaku CI; Wrapp D; Sakharkar M; Huang D; Deveau LM; Yockachonis TJ; Herbert AS; Battles MB; O'Brien CM; Brown ME; Geoghegan JC; Belk J; Peng L; Yang L; Hou Y; Scobey TD; Burton DR; Nemazee D; Dye JM; Voss JE; Gunn BM; McLellan JS; Baric RS; Gralinski LE; Walker LM
Science; 2021 Feb; 371(6531):823-829. PubMed ID: 33495307
[TBL] [Abstract][Full Text] [Related]
20. Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates.
Ren W; Sun H; Gao GF; Chen J; Sun S; Zhao R; Gao G; Hu Y; Zhao G; Chen Y; Jin X; Fang F; Chen J; Wang Q; Gong S; Gao W; Sun Y; Su J; He A; Cheng X; Li M; Xia C; Li M; Sun L
Vaccine; 2020 Jul; 38(35):5653-5658. PubMed ID: 32651113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
